Back

SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy

2023-06-27 infectious diseases Title + abstract only
View on medRxiv
Show abstract

ObjectiveTo compare the frequency of replication-competent virologic rebound with and without nirmatrelvir-ritonavir treatment for acute COVID-19. Secondary aims were to estimate the validity of symptoms to detect rebound and the incidence of emergent nirmatrelvir-resistance mutations after rebound. DesignObservational cohort study. SettingMulticenter healthcare system in Boston, Massachusetts. ParticipantsWe enrolled ambulatory adults with a positive COVID-19 test and/or a prescription for n...

Predicted journal destinations